Diagonal Therapeutics engineers first-in-class clustering antibodies that aim to repair faulty cell-signaling pathways driving severe genetic disorders. Its DIAGONAL Product Engine combines proprietary computational and experimental methods to overcome traditional antibody discovery challenges and produce optimized therapeutics. The lead program, DIAG723, targets the root cause of hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension and is the primary focus of upcoming clinical advancement. Beyond this, the company is building a pipeline of selective clustering antibodies addressing diseases in hematology, hepatology, and nephrology. Funds from the latest raise will be deployed to progress DIAG723 and further pipeline development. Diagonal is led by founder and CEO Alex Lugovskoy and has attracted several blue-chip life-science investors, underscoring strong industry confidence in its platform.

Total raised

$253M

Funding rounds

2

Latest round

Series B

Latest activity

Jan 2026